New Balloon-Based Technology for Atrial Fibrillation Treatment Debuts in Israel

For the first time in Israel, a novel catheter technology for treating atrial fibrillation (AFib) has been utilized at Laniado Hospital in Netanya. The Volt PFA system from Abbott, which combines a balloon with targeted electrical pulses, was used in two initial procedures on Thursday. This method aims to isolate the problematic areas in the heart responsible for the irregular rhythm without using heat or cold, a departure from traditional ablation techniques.

The two patients undergoing the procedure had complex underlying health conditions, including diabetes and hypertension. One patient suffered from persistent AFib, which is typically more challenging to treat. Hospital officials reported that both procedures were completed successfully, with the pulmonary veins confirmed as electrically isolated using advanced mapping technology. Long-term follow-up will be necessary to fully assess the treatment's effectiveness.

Atrial fibrillation is a common heart rhythm disorder where the upper chambers of the heart beat irregularly, potentially leading to symptoms like palpitations, shortness of breath, fatigue, and dizziness, or occurring without noticeable symptoms. Beyond impacting quality of life, AFib increases the risk of blood clots and stroke. While medications are a primary treatment, ablation is an option for maintaining a normal heart rhythm by electrically isolating specific heart regions, usually around the pulmonary veins.

Previous ablation methods relied on radiofrequency (heat) or cryoablation (cold). The newer PFA technology uses short, high-energy electrical pulses to create microscopic holes in cell membranes, leading to controlled cell destruction. The Volt PFA system's unique catheter design, featuring a balloon surrounded by eight metallic arms, is intended to ensure stable contact with the vein wall and focused energy delivery. This approach may also reduce damage to nearby tissues like the esophagus and nerves controlling the diaphragm.

Clinical studies suggest promising results, with one international study published in June 2026 in JACC: Clinical Electrophysiology showing that over 84% of patients with paroxysmal or persistent AFib experienced no documented recurrence after one year. Another prior study indicated that only 5.5% of 146 patients needed a repeat ablation within a year. However, the article notes that these studies did not include a comparative group using other devices, and further comparative research is needed to definitively establish the new catheter's superiority.

While the Volt PFA system has received FDA approval, potential risks remain. The study reported no cases of clinically significant hemolysis or acute kidney injury, nor damage to the esophagus or diaphragm nerve paralysis. However, two cases of cardiac tamponade, a serious condition involving fluid accumulation around the heart, did occur. The technology may also allow for procedures under conscious sedation instead of general anesthesia, which could be beneficial for patients with significant comorbidities.